Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

News & Events

Pioneering new treatments for leukaemia in children with Down syndrome

A team of world-leading scientists has secured $5 million in funding from the Leukaemia and Lymphoma Society to advance the fight against leukaemia in children with Down syndrome.

News & Events

Raine Foundation grants to support key child health research

Three outstanding young researchers from The Kids Research Institute Australia have been named Raine Fellows and received valuable Raine Priming Grants to support their child health research.

News & Events

Community collaboration ensures ending RHD is everybody’s business

Collaboration is the driving force behind ‘END RHD Demonstration Communities’ – a new community-driven, research-backed approach to tackling rheumatic heart disease (RHD) in remote Australia.

News & Events

New coalition to end rheumatic heart disease once and for all

Six leading health organisations have joined a new coalition to end rheumatic heart disease in Australia, disproportionately affecting Indigenous Australians.

News & Events

$2 million grant to develop diagnostic tool for rheumatic fever

The Kids Research Institute Australia & Menzies School of Health Research will lead an international project to develop a diagnostic tool for acute rheumatic fever.

News & Events

Implants could replace painful injections to treat rheumatic heart disease

Painful monthly penicillin injections to treat and prevent Rheumatic Heart Disease (RHD) could be replaced with a longer-acting implant, a recent study has found.

Research

END RHD

END RHD is an alliance of health, research and community organisations seeking to amplify efforts to end rheumatic heart disease in Australia through advocacy and engagement.

Research

Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024

Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season. 

Research

“It’s all gone quiet…” MUSIC from COVID19

Hannah Huong Christopher Moore Le Blyth OAM BSc (Hons) GradDipClinEpi PhD MA (Dev. Econ), MA (App. Stats), PhD (Econ) MBBS (Hons) DCH FRACP FRCPA PhD

Research

Childhood pneumonia in the Eastern Highlands Province of Papua New Guinea: clinical, microbiological and immunological predictors of disease

Christopher Deborah Hannah Lea-Ann Peter Blyth Lehmann Moore Kirkham Richmond MBBS (Hons) DCH FRACP FRCPA PhD AO, MBBS, MSc OAM BSc (Hons)